Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

HUGO-GTTM: Revolutionizing Humanized Mouse Models

Accelerating Drug Discovery with Precise Genome-Wide Humanization Experience accuracy and reliability in preclinical studies with HUGO-GT™ models, powered by our proprietary TurboKnockout™ technology.
Accelerating Development
Ready-to-use models speed up translational research workflows
Natural Regulation
Human gene expression mimics endogenous spatial and temporal patterns
Accurate Gene Expression
Full-length humanized gene knock-in under native murine promoter
Overview
Product
FAQs
Overview
Elevate Your Gene Therapy Research with HUGO-GT™
HUGO-GT™ revolutionizes gene therapy research by seamlessly integrating complete human genes into mouse genomes. Our advanced humanized mouse models deliver precision in disease modeling and enhanced translational relevance. Powered by proprietary TurboKnockout™ technology, HUGO-GT™ accelerates model development while ensuring exceptional reproducibility. Partner with the platform trusted by leading research institutions and pharmaceutical companies to advance drug development, therapeutic efficacy studies, and translational research.Explore how HUGO-GT™ is reshaping gene therapy research and discover its transformative impact on ongoing studies.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
Turboknockout® Gene Editing
Fast-track your research with our efficient gene targeting service.
Ophthalmic CRO Platform
Ocular disease models and IND-ready drug evaluation workflows
Gene Therapy CRO Platform
AI-guided AAV design and full-spectrum preclinical validation
Neuroscience CRO Platform
Validated CNS models with behavioral and molecular efficacy data
Antibody Discovery CRO Platform
Human antibody mice and AI tools for rapid therapeutic validation
Product
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Quantity
Main Area of Research
Additional Comments
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Selection Made Simple
Access Our Model Library >>
Base Strain
Catalog Number
Catalog NumberNameBase StrainResearch ApplicationAction
C001926B6-huCFTR*F508del/huHER2C57BL/6NCyaScreening, development, and pre-clinical evaluation of CFTR/HER2-targeted drugs; Research on the pathological mechanisms and treatment methods of cystic fibrosis (CF) and cancer.
I001047BALB/c-hCD3 (line2)BALB/cAnCyaResearch on the immune system; T cell activation and antigen recognition studies; Research on immunosuppressive therapy for autoimmune diseases; Development of CD3-targeted drugs.
C001523B6-hCALCAC57BL/6JCyaDiscovery and screening of migraine drugs and therapies; Evaluation of the efficacy and safety of migraine drugs and therapies; Research on vascular biology and blood pressure regulation; Research on cell proliferation and apoptosis; Research on tumor growth inhibition and inflammation; Research on the generation and differentiation of hematopoietic stem/progenitor cells.
C001790B6-hTREM1C57BL/6NCyaTREM1-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of inflammatory diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA); Research on the pathological mechanisms and therapeutic approaches of cancers such as glioma and hepatocellular carcinoma; Research on the pathological mechanisms and therapeutic approaches of neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD).
C001873B6-huTFRC/huSNCA(3'UTR)C57BL/6NCyaResearch on neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA); Development, screening, and preclinical evaluation of TFRC/SNCA-targeted drugs; Research on iron metabolism disorders and tumorigenesis and progression.
I001220B6-hPCSK9/Apoe KOC57BL/6CyaDevelopment, screening, and preclinical evaluation of PCSK9-targeted drugs; Research on metabolic diseases such as hyperlipidemia, stroke, coronary heart disease, familial hypercholesterolemia (FH), and other atherosclerotic cardiovascular diseases (ASCVD).
C001713B6-hIL2RAC57BL/6NCyaIL2RA-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. Tumor immunology and other anti-tumor research.
C001569B6-hMECP2*T158MC57BL/6NCyaB6-hMECP2*T158M mice can serve as a valuable model for studying the mechanisms of RTT and could potentially be used to develop or validate targeted therapies.
C001808B6-hCCR8C57BL/6NCyaCCR8-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of allergic disorders (like asthma and atopic dermatitis); Research on the pathological mechanisms and therapeutic approaches of various cancers (e.g., malignant melanoma, hepatocellular carcinoma, cutaneous T-cell lymphomas); Research on the pathological mechanisms and therapeutic approaches of chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD) and potentially multiple sclerosis (MS); Research on HIV-1 infection.
C001610B6-hATP7B*H1069QC57BL/6NCyaResearch on hepatolenticular degeneration (HLD); Preclinical evaluation of ATP7B-targeted drugs.
Items: 1 to 10 of 330
1
2
3
4
5
6
...
32
33
Previous Page
Next Page
FAQs
Frequently Asked Questions (FAQs)
How precisely can HUGO-GT™ models integrate complete human genes?
Powered by TurboKnockout™ technology, HUGO-GT™ enables precise integration of full-length human genes while retaining key regulatory features required for physiologically relevant expression. Depending on the project design, the models can reproduce human isoforms and incorporate selected regulatory elements to better reflect endogenous spatial and temporal expression. Feasibility may vary for exceptionally large genes, highly repetitive regions, or loci with particularly complex regulatory architecture, and each target is evaluated individually.
Can HUGO-GT™ support high-throughput screening and rapid custom model development?
Yes. HUGO-GT™ offers ready-to-use humanized models that can shorten study preparation timelines and support screening, efficacy, and pharmacological studies. For targets not currently available, Cyagen can rapidly develop custom humanized lines using a standardized model-generation workflow designed to deliver consistent and reproducible results.
Can human gene products trigger immune responses in HUGO-GT™ mice?
Potentially. Because human proteins may differ from their murine counterparts, they can sometimes be recognized as foreign by the mouse immune system. HUGO-GT™ models are designed to express human genes in physiologically relevant tissues and at appropriate levels, which may reduce non-physiological responses associated with artificial overexpression. However, immune tolerance depends on factors such as the target protein, sequence differences, expression pattern, and mouse background. Where immune responses may affect study outcomes, additional model design strategies or immunological assessments may be recommended.
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research